EVX-01
Phase 2 registry
Since , the date of the source that reports this phase.
Summary
EVX-01 is a program from Evaxion. The source describes it as personalized cancer vaccine. It is being developed for melanoma. ClinicalTrials.gov lists it at Phase 2 (active not recruiting) under NCT05309421. The AI role named in the source is vaccine design. Registry records: NCT05309421, Phase 2, active not recruiting, updated Sep 22, 2025. 75% ORR per post. The latest dated source is from Oct 24, 2025.
Built only from the sources listed on this page.
Facts
- Company
- Evaxion
- Indication
- Melanoma
- Therapeutic area
- Oncology
- Modality
- Personalized cancer vaccine
- AI role
- Vaccine design
- Phase in the source
- Phase 2, as of Oct 24, 2025
- Phase source
- Registry
- Board column
- Phase 2
Key readouts in the source
75% ORR per post
AI evidence
AI source: Paper
“Tumor-derived neoantigens were selected by the AI platform PIONEER and used in personalized therapeutic cancer peptide vaccines EVX-01.”
Source: paper (opens in new tab)
Trial records
- NCT05309421 on ClinicalTrials.gov (opens in new tab) Phase 2 Active not recruiting Updated
Also listed: EU CTIS 2024-512393-10-00.
Milestone timeline
-
NCT05309421 record updated
Phase 2, Active not recruiting
-
ClinicalTrials.gov record: Phase 2
75% ORR per post
Spot an error? Tell me and I'll fix it.